2024-513549-36-01RecruitingPhase 1
A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH
Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 May 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- First submitted
- 27 Jun 2024
- Start date
- 10 Sept 2024
- Lead sponsor
- Boehringer Ingelheim International GmbH
- Diseases
- Fatty liver disease (MASLD/MASH)
- EU CT number
- 2024-513549-36-01
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 124
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SGS Belgium | Edegem | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.